J Exp Med Tao Ting / Shi Hui et al. Revealed the driving factors of ganglioneuroma and provided new ideas for preoperative reduction of tumor volume
in this study, a visual illusion flash grab effect was used to separate the input orientation and the perceived orientation. The results showed that the tilt aftereffect mainly depended on the perceived orientation rather than the input orientation; and the visual cortex was revealed by high spatial-temporal resolution brain imaging technology The representation of the orientation illusion in the flash grab effect is derived from the feedback signal, which reveals that when the feedforward and feedback signals differ in the visual cortex, the feedback signal dominates the visual adaptation process.
on August 3, researchers from the Rotterdam School of management at Erasmus University in the Netherlands published a study that uncovered the neural mechanism behind cheating and determined the exact role of cognitive control in honest or cheating behavior.
they found that cognitive control helps cheaters make honest decisions, while for honest people, it makes them choose to cheat. Relevant results were published on. Using functional MRI analysis, the researchers found that more honest participants showed more lateral prefrontal cortex, posterior cingulate cortex, and bilateral temporal junction activation in the face of cheating opportunities. Participants with more cheating showed higher activity in the anterior cingulate cortex and inferior frontal gyrus when making honest decisions. That is to say, the more cheaters give up cheating, their ACC and IFG participation is more than honest participants. The results also showed that the amplitude of reward significantly regulated bilateral nucleus accumbens activity, but no significant difference was observed in different groups, that is, participants were equally sensitive to rewards, regardless of the frequency of cheating.
4. The association between brain-derived neurotrophic factor gene Val66Met polymorphism and cerebral gray matter volume in patients with first-episode untreated depression
the purpose of this study is to explore the correlation between single nucleotide polymorphism rs6265 of BDNF gene and gray matter volume of patients with untreated depression for the first time.
the results showed that there were statistically significant differences in gray matter volume of multiple brain regions in patients with Val / Val homozygous carriers and Met allele carriers compared with the control group, suggesting that the gray matter volume changes related to BDNF Val66Met polymorphism may occur in the early stage of depression. The genetic variation of BDNF rs6265 locus resulted in the decrease of gray matter volume in the left fusiform gyrus and the left parahippocampal gyrus. The decrease of gray matter volume in bilateral anterior cingulate gyrus is the result of BDNF and depression. The results suggest that BDNF Val66Met polymorphism may play an important role in the pathogenesis of depression.
the aim of this experiment was to investigate the effects of temporal attention, spatial attention and different dimensions of attention on visual processing. The researchers used the selective attention task, manipulated temporal attention through sound cue time, and manipulated spatial attention and characteristic attention by asking subjects to respond only to the target on specific color and spatial position to be concerned.
the research further expands the mechanism of how people combine different attention in order to promote selective visual processing. The combination of time and space and the effect of feature attention on N1 component indicate that temporal attention is a kind of “catalyst” and affects the selective visual processing of other attention at the early perception level. The effect of time attention may begin even before the relevant stimulus appears. At higher levels of cognitive processing, combined spatial attention and characteristic attention interact to respond to task-related stimuli. In conclusion, the ERP results of this study show that time attention contributes to task-related information processing from the early stage.
captions: when viewing the pictures, the EEG activity related to negative emotions was slightly lower in the non deceptive placebo group; during the 5000ms period of the single picture playing, the time of large fluctuation of brain wave was shorter.
Sometimes, the placebo effect still exists even if the patient knows that he or she is receiving a placebo. A newly published study brings evidence that placebo does cause physiological effects through psychological factors.
this study was led by scholars from the Department of psychology at the University of Michigan. In order to explore whether non deceptive placebo can really play a physiological role, the researchers conducted two parallel experiments to test the effectiveness of non deceptive placebo in improving mood and brain activity through subjective feelings and objective physiological indicators.
one of the authors, Dr. Ethan Kross, a professor of psychology at the University of Michigan, said: “these findings provide preliminary support that non deceptive placebo not only reflects response bias – that is, it promotes subjects to express the effects that researchers want to hear, but also has a real psychobiological effect.”
since loneliness is inevitable, if a person has a strong sense of loneliness in a certain age group, will this feeling continue to exist with the increase of age? To answer this question, a team led by than é e Franssen of Maastricht University in the Netherlands conducted a large survey. The study was published recently in the.
they found that people of all ages have different degrees of loneliness, and even some factors are common. However, due to different ages, the factors causing loneliness are also different. In addition, novel coronavirus pneumonia is also found to have different effects on loneliness during the new crown pneumonia.
on August 7, Bojian and Weicai jointly announced that the monoclonal antibody against aducanumab, an innovative therapy for Alzheimer’s disease, jointly developed by both sides, has been accepted by FDA and granted priority review qualification. The date of PDUFA is March 7, 2021. If approved successfully, aducanumab will become the first FDA approved treatment to delay the decline of clinical symptoms of Alzheimer’s disease, and the first treatment to prove that removing amyloid beta can achieve better clinical effect.
aducanumab is a monoclonal antibody in research targeting amyloid beta protein. According to the clinical data of mild cognitive impairment patients with Alzheimer’s disease and mild Alzheimer’s disease, aducanumab may affect the underlying pathophysiology of the disease, slow down cognitive and functional decline, and bring benefits to patients’ ability of daily living, including personal finance and executive Work and travel independently. 08/16/2020